KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Receivables (2020 - 2022)

Historic Receivables for Vir Biotechnology (VIR) over the last 3 years, with Q2 2022 value amounting to $7.0 million.

  • Vir Biotechnology's Receivables changed N/A to $7.0 million in Q2 2022 from the same period last year, while for Jun 2022 it was $7.0 million, marking a year-over-year change of. This contributed to the annual value of $773.1 million for FY2021, which is N/A changed from last year.
  • Vir Biotechnology's Receivables amounted to $7.0 million in Q2 2022.
  • In the past 5 years, Vir Biotechnology's Receivables ranged from a high of $1.2 billion in Q1 2022 and a low of $3.8 million during Q2 2020
  • In the last 3 years, Vir Biotechnology's Receivables had a median value of $159.0 million in 2021 and averaged $387.5 million.
  • Over the last 5 years, Vir Biotechnology's Receivables had its largest YoY gain of 44362.71% in 2022, and its largest YoY loss of 44362.71% in 2022.
  • Quarter analysis of 3 years shows Vir Biotechnology's Receivables stood at $3.8 million in 2020, then surged by 20244.18% to $773.1 million in 2021, then crashed by 99.09% to $7.0 million in 2022.
  • Its Receivables was $7.0 million in Q2 2022, compared to $1.2 billion in Q1 2022 and $773.1 million in Q4 2021.